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Abstract
Post-surgical surveillance of non-functioning pituitary adenoma (NFPA) is based
on magnetic resonance imaging (MRI) at 3 or 6 months then 1 year. When there
is no adenomatous residue, annual surveillance is recommended for 5 years and
then at 7, 10 and 15 years. In case of residue or doubtful MRI, prolonged annual
surveillance monitors any progression. Reintervention is indicated if complete
residue resection is feasible, or for symptomatic optic pathway compression,
to create a safety margin between the tumor and the optic pathways ahead
of complementary radiation therapy (RT), or in case of post-RT progression.
In case of residue, unless the tumor displays elevated growth potential, it is
usually recommended to postpone RT until progression is manifest, as efficacy
is comparable whether treatment is immediate or postponed. The efficacy of the
various RT techniques in terms of tumor volume control is likewise comparable.
RT-induced hypopituitarism is frequent, whatever the technique...
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Abstract
Post-surgical surveillance of non-functioning pituitary adenoma (NFPA) is based on magnetic resonance imaging (MRI) at 3 or 6 months then 1
year. When there is no adenomatous residue, annual surveillance is recommended for 5 years and then at 7, 10 and 15 years. In case of residue or
doubtful MRI, prolonged annual surveillance monitors any progression. Reintervention is indicated if complete residue resection is feasible, or for
symptomatic optic pathway compression, to create a safety margin between the tumor and the optic pathways ahead of complementary radiation
therapy (RT), or in case of post-RT progression. In case of residue, unless the tumor displays elevated growth potential, it is usually recommended
to postpone RT until progression is manifest, as efficacy is comparable whether treatment is immediate or postponed. The efficacy of the various RT
techniques in terms of tumor volume control is likewise comparable. RT-induced hypopituitarism is frequent, whatever the technique. The choice
thus depends basically on residue characteristics: size, delineation, and proximity to neighboring radiation-sensitive structures. Reduced rates of
vascular complications and secondary brain tumor can be hoped for with one-dose or hypofractionated stereotactic RT, but there has been insufficient
follow-up to provide evidence. Somatostatin analogs and dopaminergic agonists have yet to demonstrate sufficient efficacy. Temozolomide is an
option in aggressive NFPA resistant to surgery and RT.
© 2015 Elsevier Masson SAS. All rights reserved.
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Résumé
Après chirurgie, la surveillance des adénomes hypophysaires non fonctionnels (AHNF) repose sur l’imagerie par résonance magnétique (IRM)
réalisée 3, voire 6 mois, puis un an après l’intervention chirurgicale. En l’absence de reliquat adénomateux, une surveillance annuelle est recom-
mandée pendant 5 ans, puis 7, 10 et 15 ans après la chirurgie. En cas de reliquat ou d’image douteuse, une surveillance annuelle prolongée précisera
l’évolutivité éventuelle de la lésion. Une seconde intervention chirurgicale est justifiée en cas de possibilité d’exérèse complète d’un reliquat, de
compression symptomatique des voies optiques, afin de garder une distance de sécurité entre la tumeur et les voies optiques avant irradiation
complémentaire ou en cas de progression tumorale après radiothérapie. En présence d’un reliquat, il est le plus souvent justifié (sauf si la tumeur
manifeste un potentiel de croissance élevé) de différer la radiothérapie au moment où ce reliquat évolue, son efficacité étant comparable que le
traitement soit réalisé d’emblée ou différé. L’efficacité des différentes techniques de radiothérapie sur le contrôle du volume tumoral est comparable.
L’hypopituitarisme radio-induit est fréquent, quelle que soit la technique utilisée. Le choix dépendra donc essentiellement des caractéristiques
du reliquat (taille, limites, proximité des structures radio-sensibles avoisinantes). Avec les radiothérapies stéréotaxiques en dose unique ou hypo-
fractionnées, on espère une fréquence moindre des complications vasculaires et des rares tumeurs cérébrales secondaires ; mais le recul reste
insuffisant. Les analogues de la somatostatine et les agonistes dopaminergiques n’ont pas fait la preuve jusqu’alors d’une efficacité suffisante. Le
témozolamide peut être discuté chez les patients présentant des AHNF agressifs après chirurgie et radiothérapie.
© 2015 Elsevier Masson SAS. Tous droits réservés.
Mots clés : Adénomes hypophysaires non fonctionnels ; Adénomes gonadotropes ; Adénomes hypophysaires silencieux ; Adénomes hypophysaires non
sécrétants ; Chirurgie hypophysaire ; Radiothérapie
Despite recent progress in neurosurgery, surgical treat-
ment of non-functioning pituitary macroadenoma (NFPA) often
achieves only partial tumor resection and recurrence is frequent
without adjuvant therapy [1–11] (Table 1).
1.  Factors  for  recurrence  of  non-functioning  adenoma
Several studies have focused on factors for recurrence in
NFPA, but were often retrospective, with small series and vari-
able lengths and methods of follow-up. Criteria for recurrence
were variable, sometimes failing to make the distinction between
progression of postoperative residual tumor and true recurrence:
i.e., new tumor onset after complete resection. However, there
have been several recent meta-analyses [12,13] reporting higher
recurrence rates in NFPA than in secreting adenoma. This has
varied little over the last 30 years [14,15].
1.1.  Clinical  factors
The best identified recurrence factor is postoperative ade-
nomatous residue (Table 1). In apparently complete resection
(postoperative MRI interpreted as being normal), the recur-
rence risk is around 10–20% at 5 years and 30% at 10 years
[2,5,8,10,16–18]. In case of postoperative tumoral residue,
recurrence risk ranges from 25 to 40% at 5 years and exceeds
50% at 10 years, according to recent findings [2,5,7–11,16–18].
Chen et al. [12], in a meta-analysis of 19 studies of accept-
able quality (modern imaging, long follow-up), reported that the
recurrence rate in patients without identifiable residue (n  = 371)
was 12%, with 96% remission at 5 years and 82% at 10 years; in
case of postoperative adenomatous residue (n  = 600), the recur-
rence rate was 46%, with 56% progression-free survival at 5
years and 40% at 10 years. Mean doubling time for adenomatous
residue was 3.4 years.
Young age, gender and initial tumor size are non-systematic
recurrence factors [4,11,19,20]. Apoplexy is not a guaran-
tee of definitive remission. Recurrence risk is increased in
invasive tumor with extra-sellar progression (cavernous sinus,
clivus), but this is also a risk factor for incomplete resection
[4,10,21].
1.2.  Histologic  factors
Progression may be bound to histologic type. Prognosis is
classically poorer in silent corticotroph adenoma (SCA: 4–10%
of NFPAs). In Yamada et al.’s study [22], the cavernous sinus
was invaded in 85% of SCAs, compared to only 38% of non-
immunoreactive adenomas and 11% of gonadotroph adenomas.
Recurrence rates in SCA are comparable to those in other
NFPAs, but recurrence, when it occurs, is earlier and more
aggressive [23–26]. Prognosis in silent mixed GH-PRL adenoma
is likewise poorer [10].
As in other types of pituitary adenoma, tumor biomarker
expression could contribute to determining prognosis [27–29].
Results regarding predictive value, however, have been con-
tradictory [15,19–21,30]. Several reports found no correlation
between Ki67 and/or p53 expression and recurrence risk at 10
years [15,20]. The relation between Ki67 expression and inva-
sion is, moreover, variable [15]. However, in a recent study by
Ramirez et al., analyzing the expression of Ki67, PTTG, FGFR4
and SST2 and 5 in 74 gonadotroph and non-immunoreactive
adenomas, Ki67 (mean, 1.49) was the only biomarker with
expression linked to tumor behavior [30]: on multivariate analy-
sis, expression correlated with tumor diameter (>3 cm) and risk
of tumor recurrence (odds ratio: 1.4). Likewise Righi et al.,
studying 75 NFPAs with a mean 6 years’ follow-up, found
>3% Ki67 expression in 5% of tumors without recurrence ver-
sus 30% in those with, while mitosis index and p53 expression
were similar. Ki67 predicted recurrence with high specificity
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Table 1
Results of surgery in NFPA and recurrence risk according to postoperative tumor residue.
Authors Refs Total/without RT FU (years) Type of study Recurrence in
absence of residue
Recurrence in
case of residue
Turner et al. (1999) [1] 65/65 6.3 Retrospective 9/31 (20%) 12/34 (35%)
Woollons et al. (2000) [2] 72/22 5.3 Retrospective 2/11 (18%) 8/11 (73%)
Soto-Ares et al. (2002) [3] 51/51 5.6 Prospective 0/17 (0%) 13/34 (38%)
Greenman et al. (2003) [4] 122/108 4.2 Prospective 6/30 (20%) 41/78 (53%)
Ferrante et al. (2006) [5] 226/150 8.1 Retrospective 14/73 (19%) 45/77 (58%)
Dekkers et al. (2006) [6] 97/91 6 Retrospective 1/27 (4%) 9/64 (14%)
van den Bergh et al. (2007) [7] 122/46 8 Retrospective 1/18 (6%) 16/28 (57%)
Losa et al. (2008) [8] 436/355 4.5 Prospective PFS 5 years:
87.1%
PFS 5 years:
39.2%
O’Sullivan et al. (2009) [9] 126/126 5.7 Retrospective 0/26 (0%) 53/100 (53%)
Brochier et al. (2010) [10] 142/127 6.9 Retrospective 10/42 (24%) 46/85 (54%)
Reddy et al. (2011) [11] 144/144 6.1 Retrospective 2/29 (7%) 49/115 (43%)
Total 1603/1285 45/304 (15%) 292/626 (47%)
PFS: progression-free survival.
(89%) but poor sensitivity (54%), which suggests that new
thresholds need to be identified in these adenomas [21]. Finally,
several recent studies related Ki67 expression to tumor dou-
bling time [19,31,32]. These findings suggest that Ki67 is not
predictive of recurrence risk but could be an effective index of
progression risk in postoperative adenomatous residue. A new
adenoma classification includes markers for radiologic and/or
histologic invasiveness, and for proliferation (Ki67, p53, mitosis
index: proliferation corresponding to 2 of the 3 being abnormal),
improving the identification of residues liable to progress over
the long-term [29].
Other markers are under assessment. PTTG expression is
constant and non-discriminative [30]. Expression of subtype
2 and 5 somatostatin receptors is lower in recurrent adenoma
[33]. Cyclin D1 is a proto-oncogene implicated in oncogenesis
and pituitary invasion; recent studies, however, suggest its
expression is not practically contributive to prognosis [34,35].
Finally, other studies focused on the expression of angiogen-
esis markers, notably VEGF and FGFR4 receptors [30,36]. It
was very recently shown that endocan, a proteoglycan secreted
by endothelial cells, is expressed in pituitary adenoma: in a
series of 107 cases at 8 years’ follow-up, expression was sig-
nificantly associated with mitosis index, tumor size and risk of
progression [37]. The focus now is on identifying molecular
prognostic markers (ENC1, CLDN9, etc.), not yet available in
clinical practice [38–41].
2.  Postoperative  follow-up  of  NFPA
2.1.  Imaging
Post-surgical radiologic monitoring is essential in NFPA,
due to the frequent lack of clinical symptoms accompanying
progression. Follow-up is preferably on MRI, pituitary CT scan
being reserved to cases where MRI is contraindicated. Good
reproducibility is essential to the quality of follow-up, and can
ideally be achieved by volume acquisition with 3D reconstruc-
tion; failing this, successive acquisitions should be made under
identical technical conditions, in the same reference plane (e.g.,
coronal slices perpendicular to the subcallosal plane). It is
important, for interpretation, to provide the radiologist with the
preoperative MRI scan and operative report, and a reference MRI
scan taken 3 to 6 months after surgery. The imaging protocol
comprises thin (2–3 mm) sagittal T1, coronal T1 before and after
gadolinium injection, coronal T2, or axial T1-weighted slices.
Immediate postoperative MRI is not systematic, but may be
prescribed for suspected postoperative complications or possi-
ble early surgical revision in the days following primary surgery
[42]. Otherwise, the first MRI will be performed at 3 or 6 months
[3,43]. A 6-month interval reduces the rate of postoperative
remodeling artifacting interpretation, but a 3-month interval is to
be preferred in case of signs of large residue potentially threaten-
ing the optic pathways. Repeat MRI at 1 year is systematic. These
two MRI scans serve as references for subsequent follow-up
[3,43].
Precise interpretation of the postoperative reference MRI is
essential, to determine whether residue, and hence a risk of pro-
gression, is present. When detectable adenomatous residue is
absent or doubtful, MRI is repeated annually for 5 years and
then at 7, 10 and 15 years. Systematic radiological follow-up
can then be stopped if there are no clinical signs, recurrence or
suspect images. Adenomatous residue is associated with recur-
rence, usually within 1–5 years [14] but sometimes later, more
than 10 years after primary surgery (20% of recurrences accord-
ing to Reddy et al. [11]). In case of adenomatous residue or
suspect image, MRI is repeated annually for 5 years and then
every 2–3 years in absence of progression, the schedule being
adjusted on a case-by-case basis according to tumor size, dis-
tance from the optic pathways or doubt as to progression. Long
intervals between check-ups entail a risk of loss to follow-up,
requiring particular vigilance (Fig. 1).
At each check-up, the new MRI should be compared against
the postoperative reference [6,15,42,44]: progressive residue
increase could be overlooked if the new MRI were to be com-
pared only with the previous one, since adenoma growth is often
slow.
C. Cortet-Rudelli et al. / Annales d’Endocrinologie 76 (2015) 228–238 231
Non-sytematic immediate post operative MRI
1st MRI 3 to 6 mon ths  posto perati vely
2nd MRI at 1 yea r
no identifiable residue
Annual MRI  for 5  years, then at 7, 
10 and15 years
Cease systematic surveillance in 
absence of clinical  signs, 
identifiable residue or  doubtful  MRI
adenomatous residue or doubtful 
MRI
Annual MRI  for 5  years, then 
ever y 2-3 years if no 
progression
Fig. 1. MRI surveillance after surgery for non-functioning pituitary adenoma.
2.2.  Ophthalmologic  follow-up
In case of preoperative ophthalmologic abnormality, a check-
up is made 3 months after surgery, exploring visual acuity,
visual field, fundus and possible diplopia. The examination
is repeated every 6 months until maximum improvement is
achieved, especially when initially severe visual disorder con-
traindicated driving; such contraindications are to be regularly
reassessed over follow-up. Surveillance may then be less fre-
quent. In the absence of any visual impairment on the first
postoperative examination, follow-up can be stopped if there
is no suprasellar residue close to the optic pathways. If radi-
ation therapy (RT) is performed, prolonged annual follow-up
is necessary, especially after a hypofractionated or single-dose
regime, to screen for RT-related complications that may show
onset several years post-therapy.
2.3.  Biologic  follow-up
Biological hormonal assessment, performed 3 months
postoperatively, estimates recovery of hypopituitarism diag-
nosed preoperatively and the definitive nature of post-surgical
hypopituitarism. Hormonal exploration is repeated to adapt
replacement therapy if necessary in case of functional alarm
signs or increased volume of any residual tumor. Such deficits
are frequent after RT, requiring twice-yearly pituitary hormone
assessment, as described above in the review by Raverot et al.
3.  What  treatment  can  be  offered  for  residue  or
recurrence?
3.1.  Surgical  revision
Between 30 and 48% of NFPAs undergo surgical revision on
a trans-sphenoid approach [8,9], either early for large residue,
or later during tumoral progression.
Revision surgery does not seem to enhance tumor control,
with persistent residue in 72% of cases. Benefit is less than with
RT. Efficacy in terms of visual recovery also seems to be less
than for primary surgery (58% versus 90%). Moreover, surgical
complications are slightly more frequent [45].
Indications for revision surgery for recurrence of NFPA
should take account of the primary surgery report and of residue
size and location. Surgery is indicated for progressive residue
accessible for complete resection, which can be limited by
invasion of one or both cavernous sinuses; in case of persis-
tent or recurrent symptomatic optic pathway compression; to
obtain anatomic conditions allowing stereotactic RT (3–5 mm)
safety margins between adenoma and optic pathways; or in case
of post-RT tumor progression. Primary surgery may also be
planned in 2 steps: intrasellar resection, with a second step after
descent of the suprasellar contingent.
Remodeling of classical anatomic landmarks (sphenoidal
rostrum, sphenoid sinus septum) and impaired discrimina-
tion between different intrasellar tissues may hinder surgery.
Some authors recommend intraoperative neuronavigation in
such cases, but this remains a matter of debate.
3.2.  Radiation  therapy
After postoperative RT, recurrence risk in NFPA is consid-
erably reduced, 10-year progression-free survival being greater
than 90% in most series [7,10,12,45–50] (Table 2). A recent
meta-analysis [13] reported a relative risk of recurrence of 1.97
without versus with RT.
It is thus unsurprising that postoperative RT has been rec-
ommended as a complement to surgery for several decades,
although controversy remains as to indications and timing, due to
associated complications. Controversy persists mainly because
of the lack of randomized prospective efficacy studies for post-
operative RT in NFPA. Most studies have been retrospective and
observational, and systematic analysis is hindered by numerous
selection biases and study characteristics: varying definitions of
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Table 2
Efficacy of fractionated conformal RT on progression/recurrence risk in NFPA.
Authors Refs Number of patients FU (years) With/without RT % recurrence-free at 5 years % recurrence-free at 10 years
With RT Without RT With RT Without RT
Jaffrain-Rea et al. (1993) [46] 57 7.1 24/33 100% 70% 96% 55%
Gittoes et al. (1998) [48] 126 9 81/355 93% 68% 93% 47%
Woollons et al. (2000) [2] 72 5.3 50/22 72% 34% – –
Park et al. (2004) [49] 176 4.3 44/132 98% 85% 98% 50%
van den Bergh et al. (2007) [7] 122 8 76/46 95% 49% 95% 22%
Olsson et al. (2009) [50] 235 10 62/173 – – 94% 62%
Brochier et al. (2010) [10] 142 6.9 15/127 100% 70% 91% 52%
recurrence, varying rates of patients free of visible residue fol-
lowing surgery, varying length of follow-up (often insufficient),
and preferential selection of patients at high risk of recurrence
in RT groups. In a very few studies, RT was systematic after
NFPA surgery, but most centers reserve RT to more aggressive
tumors, large supra- or extra-sellar residual tumor or confirmed
recurrence. Such biases systematically tend to weigh against RT
in efficacy studies.
3.2.1.  Types  of  radiation  therapy
The first types of RT (known as “classical” or “conventional”)
used a small number of beams, with 2D dosage study and rela-
tively wide (and often poorly delineated) margins. High total and
fractional radiation doses led to relatively high rates of severe
complications such as cerebral necrosis and ophthalmologic
lesion. Later, particle accelerators delivering high-energy X pho-
tons instead of cobalt improved depth rendering and reduced the
radiation field penumbra. Increasing the number of beams, with
total doses of 45–50 Gy and fractionated doses of 1.8–2 Gy and
the introduction of simulators to locate target volumes accord-
ing to imaging data, with direct linkage to dose calculation,
brought further considerable improvements. The “conformal”
technique uses 3D target location and dosimetry, and multi-slice
fan-beam collimators improve targeting of complex volumes.
Finally, increasing the number of non-coplanar beams and being
able to modulate intensity further reduce irradiation of healthy
neighboring tissue.
Radiosurgery is 1-step RT. The objective is to superim-
pose target limits and the chosen reference isodose, so that
the dose diminishes rapidly beyond the target, optimizing spar-
ing of healthy adjacent structures. This requires an invasive
stereotactic frame, to achieve precise positioning within 1 mm,
a high-resolution imaging system, and 3D dosimetry. The
devices used are the Gamma-Knife (201 cobalt60 sources on a
hemisphere) and the linear accelerator (LINAC). The marginal
dose is usually 13–16 Gy in NFPA. This type of RT is feasible
only if the target volume is clearly visible, small (<2–3 cm on
the long axis) and sufficiently remote from the optic pathways
to ensure <8 Gy irradiation of the chiasm and optic nerves.
Fractionated stereotactic RT associates the ballistic precision
and multiple beam entries of radiosurgery to the principle of
healthy tissue radioprotection by fractioning. The total dose is
45–50 Gy by 1.8–2 Gy fractions.
CyberKnife is a miniaturized accelerator with a robotic
arm, enabling hypofractionated stereotactic RT (3–9 sessions,
depending on the team) with a non-invasive contention system
based on the technical and dosimetric principles of radiosurgery.
Proton therapy is not widely available and thus little used for
NFPA.
3.2.2. Results  of  radiation  therapy
3.2.2.1. Fractionated  conformal  radiation  therapy.  Many stud-
ies now have demonstrated the efficacy of fractionated RT in
preventing postoperative recurrence of NFPA (Table 2). For sim-
plicity’s sake, Table 2 presents only the more recent publications
(1991–2010), analyzing recurrence risk with sufficient follow-
up, and including both patients receiving postoperative RT and
those managed by surgery alone.
It emerges that almost all the reports show highly signifi-
cant benefit of RT for non-recurrence rates at 5 years (without
RT, 66 ±  19%; with RT, 94 ±  9%) and 10 years (without RT,
52 ±  16%; with RT, 92 ±  6%). Global relapse fell about 3-fold:
321/986 without RT (32%) versus 55/468 with (12%).
Two factors bear on the benefit of RT: length of follow-up,
accentuating the difference in recurrence even after 10 years;
and postoperative residual tumor, in presence of which RT shows
even clearer benefit, with mean global relapse falling from 62 to
17% [2,5,10]. Other factors may also influence efficacy, such as
tumor type (oncocytic tumor being the most radioresistant [51])
or irradiation field area [52], but these findings have not been
formally validated.
Late RT seems to be as effective in tumor control as imme-
diate postoperative RT [49].
3.2.2.2. Fractionated  stereotactic  radiation  therapy.  Efficacy
studies of fractionated stereotactic radiation therapy report a
smaller number of patients, with mean follow-up usually not
exceeding 5 years [53–57] (Table 3). Results are generally
similar to those of classic RT, with tumoral control achieved
in more than 95% of cases at 5 years.
3.2.2.3. Radiosurgery.  Radiosurgery is usually postoperative,
reserved for small, well-defined residues remote from the optic
pathways (Table 4).
Most studies involved smaller numbers of patients, with
2.5–6.5 years’ follow-up [58–68]. Results were generally
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Table 3
Efficacy of fractionated stereotactic RT on recurrence risk in NFPA.
Authors Refs Number of patients Recurrence (%) Median FU (years) 5-year RFS %
Milker-Zabel et al. (2001) [53] 68a 5 3.2 93
Paek et al. (2005) [54] 65 2 2.5 98
Colin et al. (2005) [55] 110a 1 4 99
Minniti et al. (2006) [56] 91a 3 2.8 98
Schalin-Jäntti et al. (2010) [57] 20 0 4.5 100
RFS: recurrence-free survival.
a Studies including functioning tumors.
similar to those of classic RT, with tumoral control achieved in
90–100% of cases at 5 years. Data for 512 patients managed in
9 North American centers showed 95 and 85% tumoral control
at 5 and 10 years, respectively [69]. Efficacy was comparable
to that of first-line treatment [70]. A recent meta-analysis found
better tumoral control in tumor volumes less than 4 ml [71].
There are no controlled studies comparing radiosurgery versus
surgery alone.
3.2.2.4.  CyberKnife  radiotherapy.  Tumoral control was
achieved in 98% of cases in 100 patients at a mean 33 months
(range: 18–118.5 months) after CyberKnife RT for NFPA
residue with or without progression [72].
Wilson et al. [68], in a recent study, compared results in
conventional fractionated RT, LINAC stereotactic radiosurgery
and fractionated stereotactic RT. Allowing for various inclusion
biases (historic series for conventional fractionated RT, smaller
tumors remote from the optic pathways for stereotactic radio-
surgery, etc.) they concluded that efficacy in terms of tumoral
control was comparable between these types of RT (Table 4).
3.2.3.  Complications  of  radiation  therapy
3.2.3.1.  Fractionated  conformal  radiation  therapy.  Hypopitu-
itarism is the most frequent complication of fractionated RT
(Table 5). Onset may be at several years, progressing over time.
It is pituitary and especially hypothalamic deficiency, thus fre-
quently associating moderate hyperprolactinemia. Frequency
ranges between 50 and 80% in follow-up exceeding 10 years
[45]: prolonged regular follow-up is thus required after RT.
Reducing total dose to <50 Gy and dose per fraction to 1.8 Gy,
increasing beam number and 3D dosimetry have succeeded in
eliminating radionecrosis [73]. Ophthalmologic complications
are rare (<1%), and sometimes late [73], associated with baseline
optic pathway involvement.
Radiation-induced cerebral tumor after conventional RT for
pituitary adenoma is a rare but well-established risk. It may
be astrocytoma [45,74], glioma or glioblastoma [47,73], sar-
coma [45,74,75] or meningioma [45,74] (observed in some cases
20 years post-RT). In a series of 426 adenomas treated by RT
between 1962 and 1994, the risk was 2% at 10 years, 2.4% at
20 years and 8.5% at 30 years [74].
Table 4
Efficacy of radiosurgery on recurrence risk in NFPA.
Authors Refs Number of patients Recurrence (%) Median FU (years) 5-year RFS %
Wowra and Stummer (2002) [58] 45 7 4.5 93a
Sheehan et al. (2002) [59] 42 2 2.5 NA
Petrovich et al. (2003) [60] 56 0 3 100a
Iwai et al. (2005) [61] 31 13 93
Picozzi et al. (2005) [62]
With Gamma-Knife 51 ND 5 51
Without Gamma-Knife 68 ND 5 90
Mingione et al. (2006) [63] 90 8 3.75 NA
Liscák et al. (2007) [64] 79 0 5 100
Pollock et al. (2008) [65] 62 3 5.4 95
Höybye and Rähn (2009) [66] 168 5 3.5 94
Losa et al. (2011) [67] 23 4 6.5
Sheehan et al. (2013) [69] 512 6,6 3 95
Mixed study
Wilson et al. (2012) [68]
RS (LINAC) 51 0 4.2 100
FSRT (LINAC) 67 9 5.1 93
FCRT 53 13 4.4 87
RFS: recurrence-free survival; FSRT: fractionated stereotactic radiation therapy; RS: radiosurgery; LINAC: linear accelerator; FCRT: fractionated conformal radiation
therapy.
a RFS at 3 years.
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Table 5
Efficacy and complications for the different types of RT.
Conventional/conformal Fractionated
stereotactic
CyberKnife LINAC Gamma-Knife
Tumoral control 5 years: 72–100%
10 years: 93–98%
20 years: 70–90%
93–100% 93–98% 93–98% 89.9–100%
Hypopituitarism with time
50–80% at >10 years
5–35% 0–20% 0–9.8% 7–40%
Ophthalmologic complications <1% <1% 0–1% <2% 0–13.7%
Secondary tumor 1.3–2% at 10 years
1.9–2.7% at 20 years
? ? ? Rare glioblastoma,
sarcoma
Radionecrosis ? Reported ?
Vascular Conventional: RR 1.5
to 4 (dose, female,
surgery)
Not reported Not reported Intracavernous carotid
stenosis, stroke
Intracavernous carotid
stenosis
Other ? ? ? ? Trigeminal neuralgia
Cognitive disorders, varying from subject to subject, have
been reported in patients followed for pituitary adenoma, but
with no clear demonstration of the involvement of RT [76] in
the absence of any prospective studies. The pathophysiology of
cognitive disorders is probably multifactorial: anatomic impact
of large adenoma, overlooked or poorly compensated hormone
deficits, surgical sequelae, etc. The impact if any of RT on quality
of life is controversial [77] and also seems to be multifactorial:
age and gender, type of surgery, possible hypopituitarism and
treatment.
Ionizing radiation may trigger a reaction cascade in endothe-
lial cells and leukocytes (expression of adhesion molecules,
cytokines and chemokines, etc.), leading to a pro-thrombotic
state and vascular inflammatory reaction. This post-RT vascular
inflammatory state may, in the medium- to long-term, induce or
aggravate atherosclerosis [78]. Hypopituitarism, whether or not
secondary to RT, may also increase vascular risk [79]. Stewart
et al. demonstrated in mouse that RT was an independent fac-
tor for lesions to irradiated arteries, with possible synergy with
known cardiovascular risk factors [80]. The first human stud-
ies were prompted by excess post-RT mortality not accounted
for by progression of the adenoma or RT-induced tumor. Vas-
cular risk is elevated in female subjects and in case of pituitary
surgery preceding RT [81]. Stroke has also been associated with
classical external (“conventional”) RT [73,79,81,82]. The spe-
cific technique may be implicated, notably the use of two lateral
beams, margin width, and use of 2D dosimetry. Vascular lesions
have not been reported following fractionated stereotactic RT,
but few studies reported such vascular complications precisely
[83].
3.2.3.2.  Radiosurgery.  In the short-term, headache (<5%), nau-
sea, asthenia and pain at the stereotactic frame anchorages have
been reported in Gamma-Knife and LINAC radiosurgery.
Following Gamma-Knife radiosurgery, the risk of visual
impairment ranges, depending on the series, from 0 to 13.7%.
Onset may be very early, within days, but is usually later, with a
reported maximum of 93 months. Several risk factors have been
identified: history of conventional RT, iterative radiosurgery,
pre-existing visual pathway involvement, multiple isocenters
[84], large tumor volume [69] and, above all, <3–5 mm distance
from the chiasm and >8 Gy [85] (or according to other authors
10 Gy [86]) irradiation planned for the chiasm. RT-induced
oculomotor impairment has been reported with Gamma-Knife
[84], sometimes being transient. Even so, the cranial nerves
passing through the cavernous sinus seem to be more radiore-
sistant than the optic nerve or the chiasm [87]: 19–23 Gy were
delivered without clinically serious impact [88,89]. Systematic
6-monthly ophthalmologic monitoring during the first 4 years
and then annually for 10 years should be implemented. A rare
clinical presentation of ocular neuromyotonia has been reported
following Gamma-Knife RT [90].
Following Gamma-Knife RT, onset of hypopituitarism is not
always screened for optimally and systematically. Follow-up
duration is variable and in many cases too short. For all these
reasons, a reliable epidemiology for these complications is diffi-
cult to determine. In the literature, the incidence of RT-induced
hypopituitarism varies between 7 and 40%. Onset may be very
late. Identified risk factors comprise target volume (>4 ml) [71],
residue proximity to the pituitary gland and stalk, maximum
dose received by the pituitary gland >15 Gy and by the dis-
tal infundibulum >17 Gy [69,91–93], no healthy pituitary gland
seen on MRI [92], pre-existing partial hypopituitarism [93], and
previous RT [69].
Radionecrosis has not been reported following Gamma-Knife
RT in NFPA, although there have been some few cases following
LINAC radiosurgery (<3%).
Rare cases of trigeminal neuralgia and intracavernous internal
carotid thrombosis [94] have been reported with Gamma-Knife
and LINAC. There are as yet insufficient data to assess the risk
of onset of cognitive disorders. Three cases of RT-induced tumor
following Gamma-Knife treatment of a pituitary lesion have
been reported [95,96].
3.2.3.3.  Hypofractionated  stereotactic  RT  (CyberKnife).  Data
are as yet very preliminary for CyberKnife, although hypofrac-
tionation should significantly reduce side effects. Treatment is
well-tolerated ophthalmologically if the chiasm and/or optic
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nerves do not receive too much radiation. A single case
of transient oculomotor involvement has been reported [97].
Hypopituitarism prevalence has been estimated at 0 to 20%.
There have been no reports of radionecrosis or secondary tumor,
but follow-up has been short.
3.2.3.3.1.  To  sum  up.  The efficacy of postoperative RT in
NFPA now seems undeniable, whatever the technique Late RT
seems to be as effective in tumor control as immediate postop-
erative RT. Benefit emerges more clearly with longer follow-up
and for larger postoperative residue. Benefit is, however, to be
weighed against known side effects, notably RT-induced hypopi-
tuitarism and secondary brain tumor. The impact of the various
types of RT on cognitive function and quality of life remains
very poorly elucidated.
Most experts now agree that immediate postoperative RT is
not indicated after complete tumor resection, as the recurrence
risk is low. Treatment can be postponed without loss of efficacy,
but regular radiological surveillance should be maintained over
a period of many years.
In the absence of significant and, especially, invasive tumor
residue, indications for RT should take account of risk factors
for regrowth, patient age and history, and any hypopituitarism.
In most cases, regular surveillance can be the first-line attitude,
with treatment postponed until the residue shows progression
and/or becomes threatening. RT is indicated if the tumor shows
elevated growth potential and the risk of hypopituitarism is not
a major problem.
The efficacy of the various types of RT is comparable in terms
of tumoral control (Table 5) and the choice depends on the size,
limits and location of the residue with respect to neighboring
neural structures and on the center’s particular experience with
the various techniques. Before indicating single-dose RT, the
risk/benefit ratio needs to be assessed: there is no point in trying
to minimize complications by adopting a low-dose attitude if
this would lead to insufficient tumoral control.
3.3.  Medical  treatment
Gn-RH agonists and antagonists have been proved ineffective
for reducing NFPA volume.
The discovery of dopaminergic receptors (especially type
D2 [98,99] [100], but also D4) and somatostatin receptors
(SST3 and SST2) [30,101] within NFPA, plus in vitro findings,
have led to dopaminergic agonists and somatostatin analogs
being deployed in NFPA. Series have been small and hetero-
geneous (inclusion criteria, treatment being administered in
first-line or not, systematically after surgery or only in case
of recurrence, efficacy assessment criteria, presence of visual
signs, comparison against control group, etc.). No long-term
prospective studies against placebo have been performed. The
dopaminergic agonists (bromocriptine, quinagolide and espe-
cially cabergoline), doses (up to 3 mg/day for cabergoline) and
treatment durations (1 to 93 months) all varied. It is difficult
to assess efficacy in terms of tumor volume in the absence
of any controlled studies. Volume reduction has been reported
[98,100,102] and seems to be associated with D2 receptor
expression (especially the short isoform) within the tumor.
Treatment sometimes leads to improvement in ophthalmologic
disorders, even if there is no significant reduction in tumoral
volume.
The somatostatin analogs and treatment duration (1–37
months) again varied between studies [103]. Volume reduction
was reported in a small percentage of cases. Treatment may
provide rapid relief of headache and visual field defect, once
again possibly independently of an antitumoral action. Somato-
statin receptor scintigraphy is non-predictive of analog effects
[103,104]. There are no data regarding tumor progression after
treatment termination. An association of dopaminergic agonists
and somatostatin analogs was tried, without improving effi-
cacy [105]. The interest of pasireotide, a novel somatostatin
analog with affinity for all SSTs except subtype 4, was sug-
gested in an in vitro study [106]; in vivo data are presently
lacking. In conclusion, none of these medical therapies has
shown sufficiently reliable significant efficacy in terms of tumor
volume to be recommended in case of failure of surgery
in NFPA.
Temozolomide is an oral alkylating agent that is effec-
tive in pituitary carcinoma and aggressive adenoma (mainly
lactotroph or corticotroph) [107]. Low tumoral expression of O6-
methylguanine DNA methyltransferase (MGMT) is associated
with good temozolomide response. A recent study [31] asso-
ciated lower MGMT expression in recurrent than non-recurrent
NFPA, suggesting a possible interest of temozolomide in aggres-
sive NFPA.
Recent reports suggest that Raf/MEK/ERK and PI3K/Akt/
mTOR (mammalian  target  of  rapamycin) pathway regulation
abnormalities are implicated in cell proliferation in pituitary
adenoma [108]. The action of rapamycin is down-regulated by
Akt phosphorylation, which in turn is reduced by SST2 stimu-
lation. Thus, an in vitro study showed rapamycin sensitization
of adenomatous cells by addition of octreotide [109], suggest-
ing a theoretic interest of concomitant somatostatin analog and
mTOR pathway inhibitor treatment.
4.  Conclusion
Post-surgically, if there is no identifiable adenomatous
residue or in case of doubtful image, prolonged regular surveil-
lance should be implemented, as the risk of complications
following secondary treatment (surgery or radiotherapy) is
greater than that of recurrence and/or complications related to
recurrence.
In case of adenomatous residue: morphology (size, lim-
its, distance from optic pathways, cavernous sinus invasion),
anatomopathology (immunohistochemistry, Ki67, p53, mitosis
index), residue progression, patient age and history and apti-
tude for regular prolonged surveillance, any hypopituitarism,
and the feasibility of and experience with secondary therapies
in the center are factors in decision-making, in agreement with
the patient, in a multidisciplinary team meeting involving the
neuroradiologist, neurosurgeon, radiotherapist and endocrinol-
ogist.
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